DE471794T1 - Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen. - Google Patents
Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen.Info
- Publication number
- DE471794T1 DE471794T1 DE199090909103T DE90909103T DE471794T1 DE 471794 T1 DE471794 T1 DE 471794T1 DE 199090909103 T DE199090909103 T DE 199090909103T DE 90909103 T DE90909103 T DE 90909103T DE 471794 T1 DE471794 T1 DE 471794T1
- Authority
- DE
- Germany
- Prior art keywords
- dye
- thiazine
- combination
- xanthene
- azure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001016 thiazine dye Substances 0.000 title claims abstract 9
- 239000001018 xanthene dye Substances 0.000 title claims abstract 8
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000000975 dye Substances 0.000 claims abstract 15
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 claims abstract 6
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical group C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims abstract 5
- 229960000907 methylthioninium chloride Drugs 0.000 claims abstract 5
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims abstract 3
- 229930187593 rose bengal Natural products 0.000 claims abstract 3
- 229940081623 rose bengal Drugs 0.000 claims abstract 3
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 claims abstract 3
- 230000003834 intracellular effect Effects 0.000 claims abstract 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims 4
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000008377 fluorones Chemical class 0.000 claims 1
- -1 hydroxyxanthene compound Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950003937 tolonium Drugs 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 229940075420 xanthine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Farbstoff, ausgewählt aus der Gruppe Xanthen- und Thiazinfarbstoffe, ausschließlich Methylenblau,
zur Verwendung in der Medizin.
2. Farbstoff nach Anspruch 1 in Form einer Fluoron- oder Hydroxyxanthenverbindung.
3. Farbstoff nach Anspruch 2 in Form von Rose Bengal oder Eosin Y oder einer Kombination oder eines
Derivats derselben.
4. Farbstoff nach Anspruch 1 in Form von Toluidinblau 0, Azure A, Azure B, Azure C oder einer Kombination oder
eines Derivats derselben.
5. Verwendung eines Xanthen- oder Thiazinfarbstoffs bei
der Herstellung eines Medikaments zur Behandlung von Virusinfektionen.
6. Verwendung nach Anspruch 5, wobei der Farbstoff aus Eosin Y oder Rose Bengal besteht und die Behandlung
derart ist, daß in virusinfizierten Zelleneine Farbstoffmenge entsprechend einer intrazellulären
mikromolaren Konzentration zwischen 0,1 und 10 bereitgestellt wird.
35
35
7. Verwendung nach Anspruch 5, wobei der Farbstoff aus Methylenblau, Eosin Y oder Rose Bengal besteht und die
Behandlung derart ist, daß eine Farbstoffmenge entsprechend einer Patientenblutkonzentration zwischen
20 und 20 0 Mikromol bereitgestellt wird.
8. Verwendung nach einem der Ansprüche 5 bis 7, wobei die Behandlung in einer Verabreichung des Farbstoffs
in Kombination mit nicht-ionisierender Strahlung besteht.
9. Antivirales Mittel zur Behandlung eines Patienten, umfassend einen pharmazeutisch akzeptablen Träger und
einen Thiazinfarbstoff, einen Xanthenfarbstoff oder eine Kombination oder ein Derivat derselben unter Ausschluß
von Mitteln, in denen der einzige Farbstoff aus Methylenblau besteht.
10. Mittel nach Anspruch 9, worin der Xanthenfarbstoff aus
Rose Bengal, Eosin Y oder einer Kombination oder einem Derivat derselben besteht.
11. Mittel nach Anspruch 9, worin der Thiazinfarbstoff
aus Toluidinblau O, Azure A, Azure B, Azure C oder einer Kombination oder einem Derivat derselben besteht.
12. Antivirales Mittel, umfassend einen Xanthen- oder Thiazinfarbstoff in Kombination mit einer Lösung,
ausgewählt aus der Gruppe Reinigungslösungen, antibakterielle Lösungen, gegen Pilze gerichtete Lösungen
und biologische Lösungen.
13. Mittel nach Anspruch 12, worin die Lösung aus einer
von Blut herrührenden biologischen Lösung besteht.
14. Verfahren zur Inhibierung einer viralen Replikation ex vivo durch Einwirkenlassen eines Xanthen- oder
Thiazinfarbstoffs auf virusinfizierte Zellen.
15. Verfahren nach Anspruch 14, worin der Farbstoff aus &ngr;
Methylenblau, Eosin Y oder Rose Bengal besteht und die Zellen einer Farbstoffkonzentration von größer
als 200 Mikromol ausgesetzt werden.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35038389A | 1989-05-11 | 1989-05-11 | |
| US38900789A | 1989-08-03 | 1989-08-03 | |
| PCT/US1990/002659 WO1990013296A1 (en) | 1989-05-11 | 1990-05-11 | Antiviral therapy using thiazine and xanthene dyes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE471794T1 true DE471794T1 (de) | 1992-07-23 |
Family
ID=26996594
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69028775T Revoked DE69028775T2 (de) | 1989-05-11 | 1990-05-11 | Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen |
| DE199090909103T Pending DE471794T1 (de) | 1989-05-11 | 1990-05-11 | Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69028775T Revoked DE69028775T2 (de) | 1989-05-11 | 1990-05-11 | Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0471794B1 (de) |
| JP (2) | JPH07119173B2 (de) |
| AT (1) | ATE143596T1 (de) |
| CA (1) | CA2055463C (de) |
| DE (2) | DE69028775T2 (de) |
| DK (1) | DK0471794T3 (de) |
| ES (1) | ES2032742T3 (de) |
| WO (1) | WO1990013296A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6090043A (ja) * | 1983-10-21 | 1985-05-21 | Nippon Shokubai Kagaku Kogyo Co Ltd | 窒素酸化物浄化用触媒 |
| DE3930510A1 (de) * | 1989-09-13 | 1991-03-21 | Blutspendedienst Dt Rote Kreuz | Verfahren zur inaktivierung von viren in blut und blutprodukten |
| US5545516A (en) * | 1990-05-01 | 1996-08-13 | The American National Red Cross | Inactivation of extracellular enveloped viruses in blood and blood components by phenthiazin-5-ium dyes plus light |
| WO1991016911A1 (en) * | 1990-05-01 | 1991-11-14 | The American National Red Cross | Decontamination of whole blood and cellular components by phenthiazin-5-ium-dyes plus light |
| US6207107B1 (en) | 1992-10-05 | 2001-03-27 | Baxter International Inc. | Steam sterilizable system for inactivating viral contaminants in body fluids |
| US5660731A (en) * | 1994-11-08 | 1997-08-26 | Pall Corporation | Filter for separating photoactive agent |
| AT406778B (de) * | 1996-04-09 | 2000-09-25 | Immuno Ag | Verfahren zur desintegration von nucleinsäuren und herstellung von qualitätsgesicherten biologischen produkten |
| US5935581A (en) * | 1996-07-24 | 1999-08-10 | Kapadia; Govind J. | Inhibitory effects of synthetic and natural colorants on carcinogenesis |
| US8974363B2 (en) | 1997-12-11 | 2015-03-10 | Provectus Pharmatech, Inc. | Topical medicaments and methods for photodynamic treatment of disease |
| US6248733B1 (en) | 1998-01-09 | 2001-06-19 | 3M Innovative Properties Company | Method for limiting the growth of microorganisms using metal-containing compounds |
| US8557298B2 (en) | 1998-08-06 | 2013-10-15 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
| US6610436B1 (en) | 1998-09-11 | 2003-08-26 | Gore Enterprise Holdings | Catalytic coatings and fuel cell electrodes and membrane electrode assemblies made therefrom |
| WO2001012181A1 (en) | 1999-08-13 | 2001-02-22 | Photogen, Inc. | Improved topical medicaments and methods for photodynamic treatment of disease |
| US6432396B1 (en) | 2000-07-06 | 2002-08-13 | 3M Innovative Properties Company | Limiting the presence of microorganisms using polymer-bound metal-containing compositions |
| EP1687286A1 (de) * | 2003-11-28 | 2006-08-09 | Photopharmica Limited | Entwicklungen bei biologisch wirksamen methylen-blau-derivaten (2) |
| SG135190A1 (en) * | 2004-02-20 | 2007-09-28 | Robert F Hofmann | Use of targeted oxidative therapeutic formulation in treatment of viral diseases |
| DK1799662T3 (da) * | 2004-09-23 | 2013-07-15 | Wista Lab Ltd | Fremgangsmåder til kemisk syntese og oprensning af diaminophenothiaziniumforbindelser, herunder methylthioniniumchlorid (MTC) |
| CN101084204B (zh) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| US20060188866A1 (en) * | 2005-02-18 | 2006-08-24 | Children's Hospital Oakland Research Institute | Diaminophenothiazine compositions and uses thereof |
| FR2899088B1 (fr) * | 2006-03-31 | 2008-06-27 | Mauna Kea Technologies Soc Par | "microscopie de fluorescence fibree a base de bleu de methylene." |
| WO2011137447A1 (en) | 2010-04-30 | 2011-11-03 | Prostetta Antiviral Inc. | Antiviral compounds |
| WO2012145567A1 (en) | 2011-04-20 | 2012-10-26 | Prosetta Antiviral Inc. | Antiviral compounds |
| JP7512409B6 (ja) * | 2020-03-26 | 2024-07-23 | プロヴェクタス ファーマテック，インク． | 腫瘍学及びウイルス学におけるハロゲン化キサンテンの新規の使用 |
| US11938182B2 (en) | 2020-03-26 | 2024-03-26 | Provectus Pharmatech, Inc. | Halogenated xanthenes as vaccine adjuvants |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA993795A (en) * | 1970-12-10 | 1976-07-27 | Richardson-Merrell (Canada) Ltd. | Antiviral compositions containing bis-basic ethers and thioethers of xanthene and xanthen-9-ones and methods of treating viruses therewith |
| US4305390A (en) * | 1975-11-28 | 1981-12-15 | Massachusetts Institute Of Technology | Method for generating oxygen in an excited electronic state and inactivation of microorganisms |
| DE3341001A1 (de) * | 1983-11-12 | 1985-05-23 | Krause, Hans Jürgen | Nanopartikel aus bioabbaubarem, synthetischem material, verfahren zu deren herstellung und ihre anwendung |
-
1990
- 1990-05-11 EP EP90909103A patent/EP0471794B1/de not_active Revoked
- 1990-05-11 DE DE69028775T patent/DE69028775T2/de not_active Revoked
- 1990-05-11 ES ES90909103T patent/ES2032742T3/es not_active Expired - Lifetime
- 1990-05-11 JP JP2508726A patent/JPH07119173B2/ja not_active Expired - Lifetime
- 1990-05-11 DE DE199090909103T patent/DE471794T1/de active Pending
- 1990-05-11 WO PCT/US1990/002659 patent/WO1990013296A1/en not_active Application Discontinuation
- 1990-05-11 AT AT90909103T patent/ATE143596T1/de not_active IP Right Cessation
- 1990-05-11 CA CA002055463A patent/CA2055463C/en not_active Expired - Lifetime
- 1990-05-11 DK DK90909103.5T patent/DK0471794T3/da active
-
1995
- 1995-05-22 JP JP7122801A patent/JP2700126B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH04507403A (ja) | 1992-12-24 |
| DE69028775T2 (de) | 1997-05-07 |
| EP0471794B1 (de) | 1996-10-02 |
| ES2032742T3 (es) | 1997-02-01 |
| JPH07119173B2 (ja) | 1995-12-20 |
| JPH08151327A (ja) | 1996-06-11 |
| EP0471794A4 (en) | 1992-05-06 |
| ATE143596T1 (de) | 1996-10-15 |
| EP0471794A1 (de) | 1992-02-26 |
| JP2700126B2 (ja) | 1998-01-19 |
| WO1990013296A1 (en) | 1990-11-15 |
| CA2055463C (en) | 1997-09-30 |
| ES2032742T1 (es) | 1993-03-01 |
| DE69028775D1 (de) | 1996-11-07 |
| DK0471794T3 (da) | 1996-11-18 |
| CA2055463A1 (en) | 1990-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE471794T1 (de) | Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen. | |
| DE68922399T2 (de) | Voraktivierte therapeutische agentien, hergeleitet von photoaktiven verbindungen. | |
| DE3855220T2 (de) | Methode zur beseitigung von infektionserregern in geweben | |
| DE69328777T2 (de) | Dekontaminierung von Plättchen mit 8-Methoxypsoralen | |
| ATE63826T1 (de) | Pumpenkoerper zum anschluss einer bestrahlungskammer an ein system zur behandlung eines patienten durch photoaktivierung. | |
| DE3705637A1 (de) | Vorrichtung zur entfernung von lokal applizierten wirkstoffen gegen solide tumoren | |
| DE236684T1 (de) | Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit. | |
| DE19533682A1 (de) | Verfahren zum Anlagern und Immobilisieren von Heparin auf anorganischen Substratoberflächen von kardiovaskulären Implantanten | |
| DE2404416A1 (de) | Neurotropisch wirksames mittel und verfahren zu seiner herstellung | |
| ATA21888A (de) | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken | |
| DE102005062634A9 (de) | Verfahren zur Inaktivierung von Pathogenen in Spenderblut, Blutplasma oder Erythrozytenkonzentraten in flexiblen Behältnissen unter Bewegung | |
| BR9007769A (pt) | Preparacao para o tratamento de tecido alheio,processo para a preparacao de tecido alheio ex-vivo antes de transplante ou de seu uso como material curativo,processo para o tratamento de um paciente,e,processo para realizacao de transplantes de orgaos alogenicos ou xenogenicos a um paciente humano,ou para fornecimento de curativo alogenico ou xenogenico a este paciente | |
| DE69902520T2 (de) | Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden | |
| DE68907430C5 (de) | Cytotoxische Therapie. | |
| Prescott et al. | Procion dyes as matrix markers in growing bone and teeth | |
| DE68907392T2 (de) | Dysmnesie modifizierende Arzneimittel. | |
| DE68928415D1 (de) | Verfahren und zusammensetzungen zur verabreichung von lipophilen heilmitteln in einer dosierung nach der gewünschten wirkung | |
| EP1307241B1 (de) | Photodynamische behandlung und uv-b- bestrahlung einer thrombozyten-suspension | |
| DE69522685T2 (de) | Behandlung von blut-plasma | |
| AT408719B (de) | Mittel zur behandlung von hepatitis c | |
| Millington | History and Cultural Aspects of Vitiligo | |
| DE4124300A1 (de) | Sonnenschutzoel | |
| Thilander et al. | Catecholamine excretion in children in connection with various types of dental treatment | |
| DE3637649A1 (de) | Verwendung von 4-chinolon-derivaten zur bekaempfung von protozoen und helminthen | |
| JPS61238726A (ja) | 細胞賦活剤 |